In this issue:
Guselkumab for hidradenitis Suppurativa
Cutaneous immune-related adverse events with ICIs
Environmental air pollution and atopic dermatitis flare with dupilumab
Adalimumab efficacy correlated with BMI
Real-world study of dupilumab in adults with atopic dermatitis
Prospective study of dupilumab-induced ocular events in atopic dermatitis
Spesolimab for moderate-to-severe atopic dermatitis
Risankizumab for hidradenitis suppurativa
Omalizumab + rituximab in refractory bullous pemphigoid
Please login below to download this issue (PDF)